Aurobindo pharma receives USFDA nod for two Dapagliflozin tablets
Aurobindo Pharma has secured USFDA approval for generic versions of diabetes treatments Dapagliflozin and Dapagliflozin/Metformin ER. These approvals, for multiple strengths, will bolster the company's US generics portfolio. Manufactured at its subsidiary's facility, the products are set for immediate launch, targeting significant market shares and potentially offering Aurobindo 180 days of shared exclusivity.
Aurobindo Pharma has secured USFDA approval for generic versions of diabetes treatments Dapagliflozin and Dapagliflozin/Metformin ER. These approvals, for multiple strengths, will bolster the company's US generics portfolio. Manufactured at its subsidiary's facility, the products are set for immediate launch, targeting significant market shares and potentially offering Aurobindo 180 days of shared exclusivity.
